About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Atlanta | 19,805 Studies Near You | Clareo Health

Clinical Trials LocationsAtlanta

Clinical Trials in Atlanta

Discover 19,805 clinical trials near Atlanta, Georgia. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 16101-16120 of 19,805 trials

TERMINATEDPhase 2< 1 mile

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914

A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155

Lymphoma, Large-Cell, DiffuseLymphoma, B-Cell Refractory

Astellas Pharma Inc41 participantsStarted Jun 2007

Beverly Hills, California, United States • Palo Alto, California, United States • Aurora, Colorado, United States +19 more locations

COMPLETEDPhase 3< 1 mile

Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis

NCT01908595

This study is to evaluate the efficacy and safety for long term use of M518101 in subjects with plaque psoriasis.

Maruho North America Inc.480 participantsStarted Aug 2013

Mesa, Arizona, United States • Bakersfield, California, United States • Los Angeles, California, United States +28 more locations

Find Trials by Condition in Atlanta

Breast Cancerin Atlanta Lung Cancerin Atlanta Prostate Cancerin Atlanta Colorectal Cancerin Atlanta Melanomain Atlanta Leukemiain Atlanta Lymphomain Atlanta Pancreatic Cancerin Atlanta Ovarian Cancerin Atlanta Brain Cancerin Atlanta Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3< 1 mile

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807923

The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Vertex Pharmaceuticals Incorporated559 participantsStarted May 2013

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Tucson, Arizona, United States +86 more locations

COMPLETEDPhase 3< 1 mile

Pediatric Intensive Care Units (ICUs) at Emory-Children's Center Glycemic Control: The PedETrol Trial

NCT01116752

The primary goal of this project is to determine whether normalizing hyperglycemia is a safe approach to improve multisystem organ function in critically ill children requiring intensive care. The will are conducting the "PedETrol" (the "Pediatric ICUs at Emory-Children's Center Glycemic Control: The PedETrol Trial) Trial, a 4-year single-center, prospective, randomized clinical trial to evaluate the outcome benefit, safety and resource utilization impact of maintaining strict glucose control in children with life-threatening conditions. \*\*\*This study is supported by an Research Project Grant (RO1 grant) (MRR) via the National Heart, Lung, and Blood Institute (NHLBI).

Pediatric Patient (1m-21y)ICU AdmissionHyperglycemia

Indiana University153 participantsStarted Aug 2010

Atlanta, Georgia, United States

COMPLETEDPhase 2< 1 mile

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

NCT01462695

This phase II trial studies how well sunitinib malate works in treating younger patients with recurrent, refractory, or progressive malignant glioma or ependymoma. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Childhood Cerebellar Anaplastic AstrocytomaChildhood Cerebral Anaplastic AstrocytomaChildhood Cerebral Astrocytoma+8 more

National Cancer Institute (NCI)30 participantsStarted Jan 2012

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Little Rock, Arkansas, United States +93 more locations

COMPLETEDPhase 3< 1 mile

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817

Cytomegalovirus (CMV) infection is known to cause hearing loss and mental retardation. The purpose of this study is to compare a 6-week course to a 6-month course of the drug valganciclovir in babies born with CMV to assess the safety and efficacy of this treatment. Participants will include 104 infants (30 days old or younger) born with CMV disease. All infants will take valganciclovir by mouth for 6 weeks. At the end of the 6 week period, subjects will be assigned by chance to receive either valganciclovir or placebo (inactive substance) to complete the 6 months of antiviral treatment. Patients will be followed for the study related evaluations of safety, changes to hearing, and developmental milestones for up to 2 years. Patients will be followed by telephone contact for an additional 3 years. Thus, participants may be involved in study related procedures for approximately 5 years.

Cytomegalovirus Infection

National Institute of Allergy and Infectious Diseases (NIAID)109 participantsStarted Jun 2008

Birmingham, Alabama, United States • Mobile, Alabama, United States • Little Rock, Arkansas, United States +45 more locations

COMPLETEDPhase 2< 1 mile

A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT01665391

The primary objectives of this trial are as follows: * to compare the achievement of a partial remission (PR) or complete remission (CR) in urinary protein: creatinine ratio (Up/c ratio) in patients treated with fresolimumab versus placebo * to compare the safety profile of patients treated with fresolimumab versus placebo The secondary objectives are as follows: * To compare the reduction in proteinuria in patients treated with fresolimumab versus placebo * To evaluate fresolimumab dose-dependent reduction in proteinuria * To compare the change in renal function (estimated glomerular filtration rate \[eGFR\]) in patients treated with fresolimumab versus placebo * To evaluate the multiple-dose pharmacokinetics of fresolimumab

Primary Focal Segmental Glomerulosclerosis

Genzyme, a Sanofi Company36 participantsStarted Aug 2012

Birmingham, Alabama, United States • Phoenix, Arizona, United States • San Francisco, California, United States +29 more locations

TERMINATEDPhase 2< 1 mile

Safety Study for the Treatment of Abdominal Aortic Aneurysms

NCT00610090

The primary study objective, at this time, is to follow out to 5 years post implant the safety of already enrolled subjects who were treated with the UniFit Aorto-uni-iliac (AUI) Endoluminal Stent Graft (the "study device") for the repair of abdominal aortic aneurysms (AAAs).

Abdominal Aortic Aneurysms

Duke Vascular, Inc.71 participantsStarted May 2007

Loma Linda, California, United States • Torrance, California, United States • Newark, Delaware, United States +16 more locations

COMPLETEDPhase 214 miles

Effect of Febuxostat on Blood Pressure

NCT01496469

The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with gout).

Takeda121 participantsStarted Feb 2012

Foley, Alabama, United States • Buena Park, California, United States • Carmichael, California, United States +42 more locations

WITHDRAWNPhase 444 miles

Clinical Evaluation of Placement of Radiofrequency-based Plasma Microdebridement in the Treatment Algorithm for Foot and Ankle Tendinosis and Plantar Fasciosis

NCT00420875

To determine the magnitude of improvement for pain and function symptoms over a two year period after enrollment into the registry study in patients presenting with chronic heel pain and receiving standard of care treatment. Standard of care will include traditional conservative care measures, ESWT, radiofrequency-based plasma microdebridement, scalpel debridement and/or surgical release.

Plantar Fasciosis, Achilles Tendinosis

ArthroCare CorporationStarted Jun 2007

Mesa, Arizona, United States • Santa Monica, California, United States • Oakwood, Georgia, United States

COMPLETED50 miles

A Retrospective Cohort Study of Infusion Reactions Due to Vectibix

NCT01156090

The purpose of this study is to identify approximately 100 - 150 patients who have received Vectibix (Panitumumab) in offices and clinics located in Tennessee, North Carolina, South Carolina, and North Georgia from February 2004 - April 2009. Information regarding the incidence and severity of hypersensitivity infusion reactions to Vectibix (Panitumumab)will be captured. In patients who experienced hypersensitivity reactions, the following information will also be collected: premedication, treatment cycle symptoms that were experienced during chemotherapy, changes required in subsequent Vectibix (Panitumumab) or chemotherapy treatment, and outcome of the hypersensitivity reaction.

Infusion Reaction

SCRI Development Innovations, LLC141 participantsStarted Jun 2010

Jonesboro, Arkansas, United States • Augusta, Georgia, United States • Gainesville, Georgia, United States +4 more locations

UNKNOWN104 miles

fFN Clinical Evaluation in Asymptomatic Women at High Risk for Preterm Birth

NCT01955148

This study is designed to determine if quantitative analysis of fetal Fibronectin (fFN) can be used to advance prediction of spontaneous preterm birth (sPTB). This will be a prospective observational multi-center study with approximately 15 to 20 US sites, and approximately 1210 subjects evaluating the clinical utility of the Rapid fFN 10Q system for preterm birth risk assessment. A single fFN specimen will be collected from each subject between 16 weeks, 0 days and 21 weeks, 6 days. The primary and secondary maternal outcome measures will be determined based on the date of delivery and the estimated date of confinement (EDC), which will be evaluated in a standardized manner.

Hologic, Inc.1,210 participantsStarted Oct 2013

Birmingham, Alabama, United States • San Diego, California, United States • Newark, Delaware, United States +13 more locations

COMPLETEDPhase 3148 miles

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040

This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).

Hypercholesterolemia

Regeneron Pharmaceuticals355 participantsStarted Oct 2012

Mobile, Alabama, United States • Chandler, Arizona, United States • Tucson, Arizona, United States +94 more locations

COMPLETEDPhase 2154 miles

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

NCT00135577

Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants with cancer pain. Study ABD101684 will serve as an extension to Study SB-767905/008 and offer continued access to blinded investigational product to participants who have completed the original study. The purpose of Study ABD101684 is to evaluate the safety and efficacy of alvimopan compared to placebo in subjects who completed Study SB-767905/008 and elected to participate in this extension study.

CancerBowel Dysfunction

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)67 participantsStarted Sep 2004

Duarte, California, United States • Fountain Valley, California, United States • La Verne, California, United States +37 more locations

COMPLETEDPhase 3223 miles

Gadobutrol Enhanced MRA of the Renal Arteries

NCT01344460

Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required. This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study. MRA and CTA images will be collected for an independent review (blinded read).

Renal Artery Obstruction

Bayer317 participantsStarted May 2011

Tucson, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +67 more locations

TERMINATEDPhase 4321 miles

Surgical Reduction of the Inferior Turbinates for Nasal Obstruction

NCT00737906

The primary goal of this post-marketing surveillance study is to assess whether surgical turbinate reduction performed using a Coblation® device is associated with reduced nasal obstruction symptoms.

Chronic RhinitisInflammation of the Nasal MucosaInflammation of Nasal Tissue

ArthroCare Corporation30 participantsStarted Oct 2007

San Diego, California, United States • Aurora, Colorado, United States • Boynton Beach, Florida, United States +2 more locations

COMPLETEDPhase 2372 miles

OTO-104 for the Treatment of Meniere's Disease

NCT01412177

The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.

Meniere's Disease

Otonomy, Inc.154 participantsStarted Nov 2013

San Diego, California, United States • Cincinnati, Ohio, United States

WITHDRAWNPhase 2514 miles

A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer

NCT01184287

The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.

Non-Small Cell Lung Cancer

Tamir Biotechnology, Inc.

Beverly Hills, California, United States • Grand Rapids, Michigan, United States • Great Falls, Montana, United States +3 more locations

COMPLETEDPhase 3577 miles

Phase III Study in Refractory Behcet's Disease

NCT00995709

The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.

Novartis Pharmaceuticals118 participantsStarted Oct 2009

Baltimore, Maryland, United States • Arlington, Texas, United States • Houston, Texas, United States +46 more locations

COMPLETEDPhase 3701 miles

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

NCT00391092

This 2 arm study will compare the efficacy and safety of Avastin plus Herceptin/docetaxel, versus Herceptin/docetaxel alone, in patients with HER2 positive locally recurrent or metastatic breast cancer who have not received prior chemotherapy for their metastatic disease. Patients will be randomized 1:1 to receive either Avastin (15mg/kg iv q3weeks) + Herceptin (8mg/kg iv loading dose and 6mg/kg iv q3weeks maintenance) + docetaxel (100mg/m2 iv q3weeks) or Herceptin + docetaxel alone. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

Hoffmann-La Roche424 participantsStarted Sep 2006

Buenos Aires, Argentina • Córdoba, Argentina • La Plata, Argentina +86 more locations

PreviousPage 806 of 991Next

in Atlanta

Heart Diseasein Atlanta